Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   11/07/2025
134,21 USD (-0,83%)
(-0,83%)   11/07/2025

10 juli 2025 · Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress · Persbericht

30 juni 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy · Persbericht

27 juni 2025 · New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA · Persbericht

25 juni 2025 · Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results · Persbericht

18 juni 2025 · Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia · Persbericht

12 juni 2025 · Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity · Persbericht

27 mei 2025 · Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies · Persbericht

16 april 2025 · Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union · Persbericht

2 april 2025 · Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease · Persbericht

24 maart 2025 · Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square · Persbericht

11 maart 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients · Persbericht

18 februari 2025 · Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments · Persbericht

31 januari 2025 · Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union · Persbericht

27 januari 2025 · FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease · Persbericht

23 januari 2025 · FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA · Persbericht

14 januari 2025 · FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease · Persbericht

19 november 2024 · Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity · Persbericht

14 november 2024 · Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease · Persbericht

31 oktober 2024 · Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference · Persbericht

29 oktober 2024 · Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases · Persbericht

Mijn selecties